<DOC>
	<DOCNO>NCT03052062</DOCNO>
	<brief_summary>The objective clinical study determine tolerance dietary supplement Lipidrive evaluation several parameter : - Various blood biological parameter - Urinary parameter - Hemodynamic indicator - Cardiac function - Anthropometric variable</brief_summary>
	<brief_title>Tolerance Study Dietary Supplement Lipidrive ( ECPH1-03 )</brief_title>
	<detailed_description>Primary objective study : Evaluate effect two dos product : - Various blood biological parameter tolerance ( preprandial ) : blood glucose , insulin , HOMA-IR , glycated hemoglobin , fructosamine , total cholesterol , triglyceride , HDL-cholesterol , LDL-cholesterol , oxidize LDL , us-CRP , creatinine , ASAT , ALAT , gGT , alkaline phosphatase , bilirubin , urea . - Urinary parameter : urea , creatinine . - Hemodynamic indicator : heart rate blood pressure . - Cardiac function : ECG . - Anthropometric variable : weight , waist , hip , waist/hip ratio , body composition use bioelectric impendence analysis . Secondary objective study : Evaluate effect high dose : - Adiponectin , leptin , TNF-α , evolution kinetics blood glucose blood insulin level follow standard breakfast , without acute administration Lipidrive dietary supplement . Two questionnaire ( one eat habit 3 day another physical sport activity ) complete various time ( cf . ) . A `` satisfaction '' questionnaire also complete end study . A serum bank create ( ghrelin , resistin , GIP , GLP-1 , IL-6 , IL-1 beta , CCK ) , stools collect V2 V5 subsequent microbiota analysis ( aliquoting perform AME2P laboratory , send sample BIOFORTIS Nantes end trial ) .</detailed_description>
	<criteria>Male Aged 45 65 year ( inclusive ) BMI 30 kg/m² ( inclusive ) 40 kg/m² ( noninclusive ) and/or waist/hips ratio &gt; 0.9 Nonsmoker smoke maximum 10 cigarette per day Stable weight least 3 month start study Regular physical activity 3 month start study , subject agree maintain level activity course study Stable eat habit 3 month start study , subject agree maintain eat habit course study Willing able comply protocol , subject agree give inform write consent Registered social security scheme Subject agree register national directory volunteer participate biomedical research Following biological screen conduct inclusion visit , runin subject include follow visit accord follow criterion : FBC clinically significant anomaly accord investigator ASAT ≤ 1.55 μkat/L ≤ 92 U/L ALAT ≤ 1.7 μkat/L ≤ 101 U/L gGT ≤ 2.55 μkat/L ≤ 152 U/L 45 ≤ Creatinine ≤ 104 μmol/L ( ± 10 % ) Total bilirubin &lt; 17.1 μmol/L ( ± 10 % ) 1.7 mmol/L ≤ Urea ≤ 8.3 mmol/L ( ± 10 % ) usCRP ≤ 5 mg/L ( ± 10 % ) . Confirmed suspect food allergy test product ( describe ) Subject chronic condition specific circumstance investigator considers incompatible participation study Subject take antidiabetic treatment Subject take liporegulating ( fibrates , statin , nicotinic acid ) antidyslipidemia drug Subject consume dietary supplement ( V0 could conduct least 1 month completely stop supplement ) Subject consume grapefruit orange juice ( enzyme inhibitor ) Subject consume food product supplement phytosterols , beta glucans , konjac , and/or cinnamon ( V0 could conduct least 3 month completely stop supplement ) ( list drawn time study ) Unstable blood pressure equal 160/95 Subject undergoing treatment , accord investigator , could interfere evaluation study criterion Subject lowcalorie diet 3 month prior study and/or intend go diet study Subject serious history anorexia nervosa , bulimia eat disorder Vegetarian vegan Extreme eat habit Subject participate another clinical study exclusion period follow previous clinical study Subject receive 4500 euros compensation since start calendar year ( sum vary accord regulation ) Subject linguistic physical incapacity provide write informed consent Refusal provide write consent Subject deprive liberty administrative judicial order , trusteeship guardianship Subject contact telephone case emergency</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>